Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Guardant Health Inc (GH)

Guardant Health Inc (GH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan Business Wire - Mon Mar 30, 7:05AM CDT

This milestone underscores the power of Guardant Health’s InfinityAI platform and real-world data to enable innovative evidence generation in rare biomarker-defined populations

GH : 89.31 (+3.61%)
GH
Why Guardant Health (GH) Stock Is Falling Today StockStory - Fri Mar 27, 12:56PM CDT

Why Guardant Health (GH) Stock Is Falling Today

GH : 89.31 (+3.61%)
RUN
3 Growth Stocks We Think Twice About StockStory - Wed Mar 25, 11:36PM CDT

3 Growth Stocks We Think Twice About

GH : 89.31 (+3.61%)
ROOT : 43.25 (-0.09%)
RUN : 13.08 (+7.74%)
Verana Health and Guardant Health Partner to Advance Precision Medicine with Real-World Data PR Newswire - Tue Mar 24, 8:15AM CDT

Combination of high quality, variable-rich, curated EHR data with genomics enhances understanding of the patient journey and aids in therapy development  

GH : 89.31 (+3.61%)
GH
3 Reasons to Avoid GH and 1 Stock to Buy Instead StockStory - Wed Mar 18, 11:06PM CDT

3 Reasons to Avoid GH and 1 Stock to Buy Instead

GH : 89.31 (+3.61%)
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 Business Wire - Wed Mar 18, 7:05AM CDT

Guardant Reveal demonstrates expanded utility in identifying new, primary cancers during minimal residual disease (MRD) monitoring Studies show strong...

GH : 89.31 (+3.61%)
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership Business Wire - Mon Mar 16, 7:05AM CDT

Partnership marks the first introduction of Shield ™ multi-cancer detection test in the region with availability across Hong Kong, Singapore and the Philippines ...

GH : 89.31 (+3.61%)
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare Business Wire - Fri Mar 13, 7:05AM CDT

Survey highlights barriers to colorectal cancer screening for adults 45 and over Overwhelming majority (92%) of Americans ages 45 and over believe blood-based...

GH : 89.31 (+3.61%)
Guardant Health’s Shield Blood-based Screening Test for Colorectal Cancer Now Accessible Through National Test Ordering and Collection Network of Quest Diagnostics Business Wire - Tue Mar 10, 7:05AM CDT

Strategic collaboration to enable streamlined and accelerated access to Shield blood-based colorectal cancer screening test across Quest’s vast network ...

GH : 89.31 (+3.61%)
GBTG
1 Russell 2000 Stock on Our Watchlist and 2 We Question StockStory - Thu Mar 5, 10:31PM CST

1 Russell 2000 Stock on Our Watchlist and 2 We Question

GH : 89.31 (+3.61%)
SRCE : 69.01 (+0.64%)
GBTG : 5.49 (+1.67%)

Barchart Exclusives

Apple Is the Best-Performing Magnificent 7 Stock in 2026. Should You Buy It for Q2? Barchart - 2 minutes ago
Amid a shaky market, Apple is emerging as the Magnificent Seven’s steadiest name. But is AAPL’s resilience enough to make it a smart buy for Q2? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.